Hematoma enlargement characteristics in deep versus lobar intracerebral hemorrhage

Figures

• 

  Figure 1. Study flowchart. Altogether, individual level data from 3,580 spontaneous ICH patients were analyzed to identify 1,954 supratentorial ICH patients eligible for outcome analyses. Data were provided by two parts of a German‐wide observational studies (RETRACE I and II) conducted at 22 participating tertiary centers, and by one single‐center university hospital registry.

• 

  Figure 2. Occurrence and extent of intracerebral hematoma enlargement. Occurrence (A) and extent (B) of hematoma enlargement in patients with deep compared to lobar ICH. Hematoma enlargement was defined as an increase in ICH volume of more than 33% or 6 mL from initial to follow‐up imaging. The extent of hematoma enlargement, that is, percentage ICH volume increase, was compared in patients actually suffering hematoma enlargement. Separate analyses were conducted for patients with non‐OAC‐ICH (n = 661), VKA‐ICH (n = 1186), and NOAC‐ICH (n = 107). Abbreviations: ICH, Intracerebral hemorrhage; NOAC, non‐vitamin‐K‐antagonist oral anticoagulant; n.s., not significant; OAC, Oral anticoagulation; VKA, vitamin‐K‐antagonist.

• 

  Figure 3. Incidence rates and time‐dependent hazard ratios for hematoma enlargement in patients with deep versus lobar ICH. (A) Incidence rates of hematoma enlargement detected through control imaging during the hyperacute course of deep and lobar ICH management in propensity‐matched cohorts. (B) Time‐dependent hazard ratios for hematoma enlargement in deep versus lobar ICH patients. Adjusted COX proportional hazard models were calculated for propensity‐matched cohorts with additional adjustment for intraventricular hemorrhage and prior oral anticoagulation to visualize the association between time since symptom onset and detection of hematoma enlargement by control imaging in patients dichotomized according to supratentorial ICH location. Hazard ratio estimates (y‐axis) for deep ICH patients were calculated at each hour since symptom onset using time‐patient‐clusters (HR estimate at the median of a 5‐hour interval) of patients with control imaging at a median of the presented hour (x‐axis) and compared with lobar ICH patients with data points within these clusters. To correct for overestimation, we weighted and smoothed hazard ratios by the method of moving averages. The dashed lines…

• 

  Figure 4. Functional outcome of patients with supratentorial Non‐OAC‐ICH and OAC‐ICH comparing patients with and without hematoma enlargement. Distribution of functional outcome and mortality at 3 months using the modified Rankin Scale (mRS, range 0–6, from 0 = no symptoms, to 5 = severe disability, and 6 = dead). Dichotomized comparison of patients with and without hematoma enlargement. The thick lines separate proportion of patients with favorable (mRS 0–3) and unfavorable (mRS 4–6) outcome as well as patients with and without 3‐month mortality. Abbreviations: ICH, Intracerebral hemorrhage; mRS, modified Rankin Scale; OAC, Oral anticoagulation.

• 

  Figure 5. Association of hematoma enlargement with 3‐month functional outcome according to ICH location and initial hematoma volume. Forest plots showing association of hematoma enlargement with functional outcome in (A) deep and lobar ICH patients and (B) deep and lobar ICH patients in relation to initial hematoma volume split according to quartiles. Multivariable modeling in both analyses (A + B) included adjustment for relevant outcome predictors, that is, age, Glasgow Coma Scale, oral anticoagulation, initial ICH volume, and intraventricular hemorrhage. Abbreviations: CI, Confidence interval; ICH, Intracerebral hemorrhage.